Discovery drug platform from GATC Health touted for accuracy

GATC Health Corp., an Irvine medtech company, said that its AI drug discovery platform can predict drug candidate success with 11 times more accuracy than the industry standard, at 88%.

The company’s study also found that its platform can predict drug failure at an “unprecedented” 84% accuracy rate. The platform can quickly assess whether a drug candidate will succeed or fail, “potentially saving billions of dollars in research and development costs,” company officials said.

The biopharma industry spent about $200 billion in 2020 on drug research and development, according to GATC. Yet, over 90% of drug candidates fail in clinical trials, according to an article published in Nature Reviews Drug Discovery.

GATC performed its study using realworld, blinded data sets on biological systems with multiple disease rates, officials said.

GATC, founded in 2021, has raised over $5 million in funding to date. The company’s CEO, John Stroh, earned his MBA from the UCLA Anderson School of Management in 1980. Stroh has previously held CEO roles at Houston-based biotech company Nanospectra Biosciences and at Irvine medical device maker NeoMatrix LLC, which was acquired by Irvine medical device manufacturer Halo Healthcare LLC in 2012.